Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.
LACOG 1818
1 other identifier
observational
584
1 country
8
Brief Summary
Survival outcomes in metastatic prostate cancer in the population Brazilian - analysis of individual characteristics and modalities of treatment in different national health institutions
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2020
Longer than P75 for all trials
8 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 14, 2020
CompletedFirst Submitted
Initial submission to the registry
June 24, 2021
CompletedFirst Posted
Study publicly available on registry
July 15, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 7, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 7, 2025
CompletedFebruary 11, 2025
February 1, 2025
5.3 years
June 24, 2021
February 10, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Describe cause-specific survival in patients with castration-resistant prostate cancer in different institutions in Brazil.
December of 2017
Secondary Outcomes (9)
To describe the sociodemographic characteristics of patients with castration-resistant metastatic prostate cancer in Brazil;
December of 2017
To describe comorbidities of patients with castration-resistant metastatic prostate cancer in Brazil;
December of 2017
To describe the clinicopathological characteristics of patients with metastatic castration-resistant prostate cancer in Brazil;
December of 2017
To compare overall survival among patients with castration-resistant metastatic prostate cancer treated in the SUS and in the private network;
December of 2017
To compare the treatments performed by patients with castration-resistant metastatic prostate cancer in the SUS and in the private network;
December of 2017
- +4 more secondary outcomes
Study Arms (2)
Public institution
Castration-resistant metastatic prostate cancer diagnosed between January 2014 and December 2017
Private institution
Castration-resistant metastatic prostate cancer diagnosed between January 2014 and December 2017
Eligibility Criteria
Diagnosis of castration-resistant metastatic prostate cancer diagnosed in the period between January 2014 and December 2017.
You may qualify if:
- Diagnosis of castration-resistant metastatic prostate cancer diagnosed in the period between January 2014 and December 2017.
You may not qualify if:
- Diagnosis of localized or locally advanced or metastatic disease sensitive to castration;
- Patients with medical records filled with incomplete data that make it impossible to evaluate the treatment received.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (8)
CPO Pucrs
Porto Alegre, Rio Grande do Sul, Brazil
Centro de Estudos e Pesquisas de Hematologia e Oncologia - CEPHO
Santo André, São Paulo, 09060-650, Brazil
Sírio Libanês
São Paulo, São Paulo, 01308-050, Brazil
Centro Paulista de Oncologia
São Paulo, São Paulo, Brazil
Hospital Santa Marcelina
São Paulo, (11) 2070-6000, Brazil
BP - A Beneficência Portuguesa de São Paulo
São Paulo, 01.323-030, Brazil
Irmandade da Santa Casa de Misericórdia de São Paulo - Hospital Central
São Paulo, 01221-010, Brazil
A.C.Camargo Cancer Center
São Paulo, 01525-001, Brazil
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Fernando Cotait Maluf
Latin American Cooperative Oncology Group
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 24, 2021
First Posted
July 15, 2021
Study Start
January 14, 2020
Primary Completion
May 7, 2025
Study Completion
May 7, 2025
Last Updated
February 11, 2025
Record last verified: 2025-02